Industry experts answer questions around future biopharma manufacturing trends, challenges, technologies, performance metrics, risk mitigation, people, and outsourcing.
We connected with a collection of biopharma financial experts to get you prepared for JPM, BTS, and the BIO CEO & Investors Conference in the first quarter of 2019.
Biopharma executives in companies of all sizes share their views on whether the now dominant life sciences industry business model, with its focus on rare diseases affecting small patient populations, allows companies to meet their historical public-health obligation.
What does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? We spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.
We asked multiple biopharma CEOs everything from which executives or companies they pay close attention to in and outside of their industry, to questions about geopolitical issues, tech trends, and everything in between.
To get to a full digital dialogue that includes everything from AI to blockchain to machine learning, drug sponsors and CDMOs alike will need to muster their resources to usher in what the rest of the world already calls Industry 4.0.
Though the FDA has outlined many promising efforts to help the U.S. biosimilar market grow, the biosimilar industry’s public comments reveal an increasing need for the U.S. government healthcare agencies to take even greater charge of biosimilar policy in 2019.
The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.
Liz Barrett recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.
Karen Aiach had no background in healthcare when her young daughter received a diagnosis of a rare form of Sanfilippo syndrome. Aiach built her company, Lysogene, to create the world’s first treatment for the terrible disease.
When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.
The heads of the East and West Coast Innovation Centers for Bayer Healthcare discuss their parallel missions, therapeutic areas of focus, and dealmaking models.
When Celgene began pursuing an aggressive acquisition strategy, David Stirling, Ph.D., a cofounder, decided to leave and eventually start his own company, BioTheryX.
Don DeGolyer talks about the process he took to go from working at a Big Pharma like Sandoz to founding and running his own small specialty pharma company.
Helen Torley, president and CEO of Halozyme Therapeutics, discusses hyaluronan and the role it plays in development of ENHANZE, PEGPH20 along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her approach to preparing and presenting as a first-time CEO at the annual J.P. Morgan Healthcare Conference.
Seven biopharmaceutical industry thought leaders weigh in on technology, tax cuts, and the political landscape to help you get ready for the coming year.
Rob Wright shares experiences from day two of recent press tour of the Netherlands’ biopharmaceutical industry.
Rob Wright shares what makes the CNS Summit the best conference he has ever attended.